更正：B7-H3 CAR-T 细胞清除肝内胆管癌并诱导持久应答
Correction: B7-H3 CAR T cells eradicate intrahepatic cholangiocarcinoma and induce durable response.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
胆管癌的免疫治疗：治疗策略和预测性生物标志物
英文原题：Immunotherapy of cholangiocarcinoma: Therapeutic strategies and predictive biomarkers.
查看英文原题
Immunotherapy of cholangiocarcinoma: Therapeutic strategies and predictive biomarkers.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
胆管癌（CCA）是一组起源于胆道树的恶性异质性肿瘤。CCA 已成为一个全球性健康问题，其发病率和死亡率不断上升，威胁着人类健康。CCA 的免疫微环境以丰富的癌相关成纤维细胞和抑制性免疫成分为特征。转录组学研究知识的不断增加和近期进展使人们对 CCA 的免疫格局有了深入了解，为更好地应用免疫治疗铺平了道路。免疫治疗主要适用于错配修复缺陷和高微卫星不稳定的有限 CCA 亚群。由于缓解率和治疗效果有限，研究人员正在探索联合策略和替代方案的新策略，如免疫疫苗和过继细胞治疗。生物标志物识别对于患者选择也至关重要。我们提供了关于 CCA 患者免疫治疗当前研究的最新总结，涵盖免疫检查点抑制剂之外的临床前和临床探索、免疫疫苗和过继细胞治疗。此外，我们综述了 CCA 免疫治疗有前景的生物标志物并讨论了近期进展。
展开英文摘要原文
Cholangiocarcinoma (CCA) is a group of malignant heterogeneous cancer arising from the biliary tree. CCA has become a global health problem with rising incidence and mortality that threatens the health of human beings. The immune microenvironment of CCA is characterized by abundant cancer-associated fibroblast and suppressive immune components. The increasing body of knowledge and recent developments in transcriptomic studies have given insight into the immune landscape of CCA, paving the way for better application of immunotherapy.
Immunotherapy mainly applies in a limited subset of CCA with deficient mismatch and high microsatellite instability. With limited response rates and treatment efficacy, researchers are looking into novel strategies on combination strategies and alternatives, such as immune vaccines and adoptive cell therapy. Biomarker identification is also critical for patient selection.
We present an up-to-date summary of the current research on immunotherapy for CCA patients, covering pre-clinical and clinical exploration beyond immune checkpoint inhibitors, immune vaccines, and adoptive cell therapy.
In addition, we review the promising biomarkers for CCA immunotherapy and discuss recent development.
论文信息
- 作者
- Chen R、Zheng D、Li Q、Xu S、Ye C、Jiang Q、Yan F、Jia Y
- 第一作者单位
- Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, Hangzhou, Zhejiang, China.China
- 通讯作者单位
- Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, Hangzhou, Zhejiang, China. Electronic address: software233@zju.edu.cn.China
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Cancer letters2022 Oct 10
- 原文标识
- PubMed 35921970 · DOI 10.1016/j.canlet.2022.215853